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Post-transcriptional regulations) are cytoplasmic domains that have been implicated in critical steps of the
regulation of gene expression, including mRNA decay and post-transcriptional gene silencing. Previously, we
reported that PCBP2 (Poly-(rC) Binding Protein 2), a facilitator of IRES-mediated translation, is a novel P-
body component. Interestingly, PCBP2 is recruited to only a subset of Dcp1a-positive P-bodies, which may
reﬂect functional diversity among these structures. In this study, we examined the selective P-body
localization of PCBP2 in detail. Co-localization studies between Dcp1a and PCBP2 revealed that PCBP2 is
present in ∼40% of P-bodies. While PCBP2 was more likely to reside in larger P-bodies, P-body size did not
seem to be the sole determinant, and puromycin-induced enlargement of P-bodies only modestly increased
the percentage of PCBP2-positive P-bodies. Photobleaching experiments demonstrated that the accumulation
of PCBP2 to speciﬁc P-bodies is a dynamic process, which does not involve the protein's transcription-
dependent nucleo-cytoplasmic shuttling activity. Finally, we found that PCBP1, a close relative of PCBP2,
localizes to P-bodies in a similar manner to PCBP2. Taken together, these results establish the compositional
diversity among P-bodies, and that PCBP2, probably in complex with other mRNP factors, may dynamically
recognize such differences and accumulate to speciﬁc P-bodies.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionMammalianprocessing bodies (P-bodies), or GWbodies, are dynamic
cytoplasmic structures that are highly enriched in mRNA decay factors,
translational repressors and post-transcriptional gene silencing machi-
nery. Initially, it was proposed that P-bodies represent actual sites of
mRNA degradation [1,2]. Subsequently it became apparent that they also
serve as storage sites of mRNAs [3,4], and could be involved in short
interfering RNA (siRNA)- and micro-RNA (miRNA)-dependent transla-
tional repression, [5–8]. The fact that P-bodies are well conserved from
yeast to mammals strongly indicates signiﬁcant roles of these structures
in RNA metabolism. While most of the P-body components identiﬁed to
date seem ubiquitously present in P-bodies, it was recently reported that
there could be differenceswithin a populationof P-bodies even in a single
cell, suggesting the existence of compositional, and possibly, functional
diversity among P-bodies [9,10]. Indeed, Pillai et al. showed that trans-
lationally repressedmRNA (and let-7 miRNA) was enriched in some, but
not all of P-bodies, suggesting that P-bodies may be comprised of two
populations, one for storageofmRNAand theother for its degradation [8].
More recently, Mozar et al. and Cougot et al. showed that heterogeneity
does exist in P-bodies in mammalian astrocytes/astrocytoma cells and, Graduate School of Arts and
u, Tokyo 153-8902, Japan. Tel.:
@anat3.med.osaka-u.ac.jp,
ll rights reserved.neurons, respectively [11,12]. Previously, we identiﬁed the RNA-binding
protein PCBP2 (Poly-(rC) Binding Protein 2), or αCP2, as a novel
component of P-bodies [13]. PCBP2 has been characterized for its ability
to stimulate IRES (Internal Ribosomal Entry Site)-mediated translation
[14,15], is reported to associate with polysomes [16], and stabilizes
speciﬁc transcripts by binding to the 3′ untranslated region [17,18]. PCBP2
is alternately known as hnRNP (heterogeneous nuclear ribonucleopro-
tein)-E2, a member of shuttling hnRNPs, and may be involved in the
export of nascentmRNPs. Interestingly, PCBP2did not localize to all of the
P-bodies as veriﬁed by immunostaining of Dcp1a. In this study, we exa-
mined such “selective” localization of PCBP2 to P-bodies in detail using
immunoﬂuorescence microscopy and photobleaching experiments. Our
results indicate that accumulation of PCBP2 to speciﬁc P-bodies is a
dynamics process that does not seem to involve its nuclear history, and
that the presence of this protein likely reﬂects compositional diversity of
repressed mRNP complexes.
2. Materials and methods
2.1. Reagents and antibodies
Actinomycin D, bromo-deoxyuridine (BrdU), puromycin, sodium
arsenite and thymidine were purchased from Sigma. Hoechst 33342
was obtained from Molecular Probes. The following primary
antibodies were used for immunoﬂuorescence: mouse anti-BrdU
antibody (Molecular Probes), rabbit anti-Dcp1a antibody (a kind gift
from Dr. Jens Lykke-Andersen), rat anti-HA antibody (Roche), rabbit
879K. Fujimura et al. / Biochimica et Biophysica Acta 1793 (2009) 878–887anti-hnRNP A3 antibody (a kind gift from Dr. Ross Smith), mouse
anti-PCBP2 antibody (Abnova), mouse anti-PTB antibody (Calbio-
chem) and goat anti-TIA1 antibody (Santa Cruz Biotechnology).
Alexa-conjugated secondary antibodies were purchased from Mole-
cular Probes.Fig. 1. Selective localization of PCBP2 to P-bodies. (A) HeLa cells expressing YFP-tagged PCB
images taken in 0.7 μm steps were 3D-reconstructed using Zeiss AIM software. (B) Wild typ
Arrows indicate co-localization, whereas arrowheads indicate the lack of co-localization. M
P-body-localization) are shown below. (C) HeLa cells expressing both YFP-tagged PCBP2 and
Arrows indicate co-localization, whereas arrowheads indicate the lack of co-localization. Ba2.2. Cell culture and transfections
HeLa cells and Neuro2a cells were grown in Dulbecco's
Modiﬁed Eagle's medium (DMEM) supplemented with 10% FCS
(Gibco-Invitrogen) as described previously [19]. Differentiation ofP2 were immunostained for Dcp1a and viewed with a confocal microscope. Z-section
e HeLa cells were doubly immunostained for Dcp1a and PCBP2 and processed as in (A).
agniﬁed images of the boxed region (with slight contrast enhancement to emphasize
HA-tagged Ago1 were immunostained with anti-HA antibody and processed as in (A).
rs=10 μm.
880 K. Fujimura et al. / Biochimica et Biophysica Acta 1793 (2009) 878–887Neuro2a cells was induced as described previously [19]. Transient
transfections of plasmids were performed using Effectene reagent
(Qiagen) following the manufacturer's instructions. For cell
synchronization, conventional double thymidine block was utilized.
Brieﬂy, HeLa cells were cultured for 2 days to reach ∼50% con-
ﬂuency, and then incubated in a medium containing 2 mMFig. 2. Incomplete overlapping of ﬂuorescence signals from PCBP2 and Dcp1a. Four consecuti
using an Alexa-conjugated secondary antibody are presented. Green and red arrows in thema
in PCBP2 and Dcp1a, respectively. Images were acquired such that no saturation in ﬂuorescthymidine for 19 h. Subsequently, cells were washed with PBS,
maintained in regular medium for 9 h, followed by secondary
incubation in 2 mM thymidine for 16 h. Afterwards, cells were
released from thymidine treatment and subjected to immunoﬂuo-
rescence. Pulse-labeling with BrdU was performed to ensure the
quality of synchronization.ve z-sections of a representative HeLa cell expressing YFP-PCBP2 co-stained with Dcp1a
gniﬁed images of the boxed region indicate subcompartments within P-bodies enriched
ence signals would occur. Bar=10 μm.
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Constructs encoding YFP-tagged and HA-tagged PCBP2 were as
described previously [13]. The expression vector for FLAG/HA-
tagged Ago1 was purchased from Addgene, which was origi-
nally constructed in Dr. Thomas Tuschl's lab [20]. The plasmid
encoding CFP-tagged Dcp1a was constructed by inserting the
Dcp1a cDNA into ECFP-C1 vector (Clontech). Human PCBP1 cDNAFig. 3. Cell cycle and P-body-localization of PCBP2. HeLa cells were synchronized by double th
panels show BrdU staining of the synchronized cells. Note that P-body size increases as celwas ampliﬁed from I.M.A.G.E. clone (clone ID: 6061411) pur-
chased from Open Biosystems and cloned into EYFP-C1 vector
(Clontech).
2.4. Immunoﬂuorescence
Indirect immunoﬂuorescence was performed as described pre-
viously [13]. All the primary antibodies were added at a dilution ofymidine blocking and stained for Dcp1a and PCBP2 after 3 h (A) or 9 h (B) release. Upper
ls progress from S-phase into G2/M phase. Bars=10 μm.
882 K. Fujimura et al. / Biochimica et Biophysica Acta 1793 (2009) 878–8871:400, incubated for 2 h at room temperature, followed by secondary
antibodies added at a 1:400 dilution.
2.5. Fluorescence microscopy
Samples were viewed with a 63× oil-immersion PlanApo lens on an
Axiovert135ﬂuorescencemicroscope (Carl Zeiss). Imageswere acquired
with a confocal laser scanning microscope (LSM510 Meta, Carl Zeiss),
from at least nine ﬁelds of view for each experiment, which was
performed in triplicate. For imaging of ﬁxed cells, laser power was set at
1% of diode laser (405-nm line), 1% of 25 mWargon ion laser (488-nm
line), 20% of 1 mWHelium-neon laser (543-nm line) and 20% of 5 mW
Helium-neon laser (633-nm line), to visualize Hoechst33342, YFP or
Alexa-488, Alexa-546, and Alexa-647, respectively. For FRAP experi-
ments, laser power was set at 10% of 30 mW argon ion laser (458-nm
line) and 1% of 25 mWargon ion laser (514-nm line) to detect CFP and
YFP, respectively. Images were acquired 0.7 μm stepwise and 3D
reconstructed using Zeiss AIM software (version 3.2). Quantitative co-
localization analyses were doubly performed on 3D images by 1)
manual counting and 2) using the analysis program provided by Zeiss
LSM software. In the former method, line proﬁles were obtained and
ﬂuorescence intensity of P-body-localized PCBP2 and cytoplasmically
diffuse PCBP2 was compared when necessary. In the latter method,
pixels above background ﬂuorescence were evaluated using the cross-Fig. 4. The effect of puromycin treatment on P-body-localization. (A) HeLa cells were treated w
immunostained for Dcp1a and PCBP2. Arrows indicate co-localization, whereas arrowheads
PCBP2. Percentage of P-bodies enriched in PCBP2 was calculated for cells treated with purom
at least 50 cells. Bars=10 μm.hair function, and the results of the co-localization analysis were
superimposed on image channels for quantiﬁcation of PCBP2-enriched
P-bodies. This procedure was repeated for 50 cells in triplicate.
2.6. Fluorescence Recovery after Photobleaching (FRAP)
FRAP experiments were performed essentially as described
previously [13]. Brieﬂy, HeLa cells were plated on glass-bottomed
dishes and doubly transfected with plasmids encoding CFP-Dcp1a and
YFP-PCBP2. After cultured overnight, FRAP experiments were per-
formed using a confocal microscope (LSM510 Meta, Zeiss) using the
458-nm line for detecting CFP, and the 488-nm line to photobleach
and detect YFP, with a pinhole adjustment resulting in a 2 μm optical
slice. A single P-body containing both CFP-Dcp1a and YFP-PCBP2 was
selected, and a 2 μm square area that enclosed the target P-body was
deﬁned as ROI (region of interest). The ROI was photobleached, and
the ﬂuorescence recovery was measured every 4 s, which was
repeated for 15 different cells. For quantitative analyses, background
intensity was subtracted and intensities of selected P-bodies were
measured over time and normalized using intensities of a region of
interest (ROI) in the nucleus of a transfected but non-bleached cell. In
the case of actinomycin D-treated cells, normalization was performed
using intensities of a ROI in the cytoplasm of a transfected, non-
bleached neighboring cell.ith puromycin (25 μg/ml,1 h) to accumulate non-translatingmRNAs into P-bodies, and
indicate the lack of co-localization. (B) Quantitative analyses of P-body-localization of
ycin for 1 h or 3 h and for control cells. The experiments were performed in triplicate for
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3.1. Selective P-body-localization of PCBP2
To conﬁrm the limited localization of PCBP2 to P-bodies, we
examined the subcellular distribution of PCBP2 by 1) expression ofFig. 5. Dynamic accumulation of PCBP2 to P-bodies. (A) FRAP experiments. HeLa cells doubly
analysis as described in Materials and methods. The recovery kinetics of YFP-PCBP2 is p
immunostained for Dcp1a and PCBP2. Nuclei were counterstained with Hoechst 33342. A s
PCBP2. (D) FRAP experiments were performed for doubly transfected HeLa cells treated with
shows time-lapse micrographs of a photobleached cell. Bars=10 μm.YFP-tagged PCBP2, and 2) immunostaining endogenous PCBP2
using an antibody speciﬁc to PCBP2, accompanied by immunostain-
ing of Dcp1a to visualize P-bodies. Images were 3D reconstructed to
make sure that all of the P-bodies and ﬂuorescence signals were
captured in the analysis. As shown in Fig. 1A and B, in both cases,
PCBP2 was enriched only in a subset of P-bodies. Quantitativetransfected with plasmids encoding YFP-PCBP2 and CFP-Dcp1a were subjected to FRAP
resented in (B). (C) HeLa cells were treated with actinomycin D (5 μg/ml, 3 h) and
ingle optical section is presented. Arrows indicate co-localization between Dcp1a and
actinomycin D. The upper panel shows the recovery kinetics, whereas the lower panel
Fig. 5 (continued).
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approximately 40% (shown in Fig. 4B). We tested this selectivity
using another P-body marker, Ago1 [6]. When HA-tagged Ago1 was
expressed in HeLa cells and co-stained with PCBP2, PCBP2 was again
localized to a subpopulation of Ago1-positive P-bodies, while
ﬂuorescence signals from Ago1 predominantly overlapped with
those of Dcp1a (Fig. S1A). These results reafﬁrmed the limited P-
body localization of PCBP2. Generally, PCBP2 was more likely
enriched in larger P-bodies, even though this was not always the
case, since some above-average sized P-bodies lacked PCBP2 (Fig.
1B, yellow arrowheads). Furthermore, an up-close look at individual
P-bodies revealed that the ﬂuorescence signals of Dcp1a and PCBP2
were not always completely overlapped, when PCBP2 was detected
by the expression of YFP-tagged fusion protein (Fig. 2) or by
immunostaining of endogenous PCBP2 (Fig. S1B): especially at the
periphery of each P-body, the two signals were distinguishable,suggesting that PCBP2 assumes distinct distribution within indivi-
dual P-bodies from Dcp1a.
3.2. Correlation with the cell cycle
Previously, it was reported that P-body size and number
dramatically changes during cell cycle [21]. To study the correlation
of cell cycle with the selectivity of P-body-localization, routine
thymidine block and release method was employed. After synchro-
nized at G1/S phase, HeLa cells were released from thymidine
treatment and subjected to immunoﬂuorescence using antibodies
against Dcp1a and PCBP2. In parallel experiments, synchronized HeLa
cells were pulse-labeled with bromo-deoxyuridine (BrdU) and
immunostained using anti-BrdU antibody to monitor the efﬁciency
of synchronization. At 3 h, bright BrdU staining was observed for
almost 100% of cells, suggesting that the synchronized cells were
885K. Fujimura et al. / Biochimica et Biophysica Acta 1793 (2009) 878–887uniformly in S phase (Fig. 3A, upper row). At 9 h, no BrdU stainingwas
observed, and subsequently the cells underwent mitosis, indicating
that the synchronized cells progressed into G2 phase at this period
(Fig. 3B, upper row). During S phase, P-body size was generally
smaller (Fig. 3A, lower row), whereas it became larger in G2 phase
(Fig. 3B, lower row), in agreement with the report by Yang et al. [21].
In accordance with the above observation that PCBP2 is likely present
in larger P-bodies, PCBP2 seemed more prevalently localized to P-
bodies in G2 phase than in S phase, indicating that its P-body
localization may be cell cycle-dependent. However, PCBP2 was
present in P-bodies of above-average size during S phase (Fig. 3A,
arrows), and a portion of P-bodies, especially smaller ones, were
PCBP2-negative even during G2 phase (Fig. 3B, arrowheads). These
observations led us to speculate that P-body-localization of PCBP2
appeared dependent on cell cycle only as a consequence of reduced (S
phase) or increased (G2 phase) prevalence of larger P-bodies, and that
P-body size may be a more dominant factor.
3.3. The effect of puromycin on the selectivity
Several studies reported P-body size and number increase by
puromycin, a translational inhibitor that triggers premature termina-
tion of polypeptide chain and polysome disassembly [22–24].
Puromycin treatment leads to the accumulation of non-translatable
mRNPs, thereby rendering the mRNA degradation machinery limiting
[25], resulting in signiﬁcant enlargement of P-bodies. To test the
possibility that puromycin-induced enlargement of P-bodies causes
more ubiquitous P-body localization of PCBP2, PCBP2 and Dcp1a were
immunostained in cells treated with this drug. As shown in the left
panel of Fig. 4A, puromycin treatment (25 μg/ml, 1 h) resulted in
signiﬁcant enlargement of Dcp1a-positive P-bodies. Quantitative
analysis revealed that the percentage of PCBP2-positive P-bodies
increased from approximately 40% to around 60%, underscoring the
importance of P-body size in recruiting PCBP2. However, considerable
portion (∼40%) of the P-bodies, including large ones (yellow arrow-
heads), still lacked PCBP2 (Fig. 4A, arrowheads; Fig. 4B) even after
longer hours of treatment (Fig. 4B, 3 h). Collectively, these data
indicate that while puromycin-induced loading of repressed mRNPs,
and the resulting enlargement of P-bodies, led to more prevalent P-
body localization, they are not sufﬁcient for ubiquitous recruitment of
PCBP2.
3.4. Dynamic accumulation of PCBP2 to P-bodies
Next, to address whether PCBP2 remains anchored to speciﬁc P-
bodies or it could exchange between P-bodies and the cytoplasm, we
performed Fluorescence Recovery after Photobleaching (FRAP) expe-
riments. HeLa cells were doubly transfected with plasmids encoding
CFP-Dcp1a and YFP-PCBP2, and FRAP experiments were performed on
YFP-PCBP2 using a confocal microscope. A single P-body enriched in
both CFP-Dcp1a and YFP-PCBP2 was chosen, the YFP signal was
photobleached and the ﬂuorescence recovery was monitored. As
shown in Fig. 5A and B, YFP-PCBP2 localized in P-bodies exhibited
rapid ﬂuorescence recovery, suggesting that PCBP2 is not tethered to
particular P-bodies but dynamically moves in and out of them. This
also indicates that PCBP2 diffusely distributed in the cytoplasm is
capable of recognizing only speciﬁc P-bodies. Since PCBP2 is also
known as a shuttling hnRNP, it may have the ability to escort nascent
mRNPs from the nucleus to storage particles in the cytoplasm, remi-
niscent of maternal germ granules [4]. Therefore, we examined the
involvement of the nucleo-cytoplasmic shuttling activity of PCBP2 in
P-body-localization. To this end, HeLa cells were treated with the
transcription inhibitor, actinomycin D (actD). A short period (3 h) of
actD treatment did not signiﬁcantly affect P-body integrity in our
experiments, unlike in long-term treatments [1], and neither PCBP2
localization nor P-body integrity was perturbed when incubated withDMSO vehicle (data not shown). PCBP2 became almost completely
relocalized to the cytoplasm upon actD treatment (Fig. S1C),
indicating that this protein belongs to the class of hnRNPs whose
nuclear import is coupled to transcription [26], and that its shuttling
activity was stalled by the drug treatment. However, its localization to
P-bodies was not perturbed (Fig. 5C). Furthermore, dynamics of P-
body-localized PCBP2 was barely affected by actD, as demonstrated by
FRAP experiments using actD-treated HeLa cells (Fig. 5D). Taken
together, these results indicate that recognition of particular P-bodies
by PCBP2 is a dynamic process which does not require its nucleo-
cytoplasmic shuttling activity and probably, its nuclear history.
3.5. P-body-localization of PCBP1, a homolog of PCBP2
Lastly, to test if there is any other factor that exhibits similar P-body
localization, we focused on PCBP1 (Poly-(rC) Binding Protein 1,
alternately hnRNP-E1), a protein that shows greater than 80% homo-
logy in its amino acid sequence. PCBP1 is also functionally related to
PCBP2, particularly in its ability to stimulate IRES-mediated transla-
tion and to stabilize speciﬁc transcripts [13,27]. We transfected a
plasmid encoding human PCBP1 fused to YFP into HeLa cells and
studied PCBP1 localization. Consistent with a previous report [28], we
found that PCBP1 was predominantly nuclear, with particular
enrichment in nuclear speckles (data not shown). However, a small
portion of the protein was cytoplasmic, and as shown in Fig. 6A,
similar to PCBP2, PCBP1 was enriched only in a subset of Dcp1a-
stained P-bodies. Interestingly, PCBP1 appeared to occur in P-bodies
less frequently than PCBP2. Upon exposure to arsenite, PCBP1
similarly became localized to both P-bodies and SGs (Fig. S2). To
study if P-body-localization of PCBP1 and PCBP2 is correlated, we co-
expressed YFP-tagged PCBP1 and HA-tagged PCBP2 and examined
their localization alongside with Dcp1a (We decided to detect PCBP2
using HA-tagged fusion protein to avoid the possibility that PCBP2
antibody might label exogenously expressed PCBP1 because of the
sequence similarity). Co-staining of PCBP1 and PCBP2 revealed that
PCBP1 was indeed more selective in P-body localization, since a
portion of the P-bodies that are enriched in PCBP2 lacked PCBP1
(Fig. 6B, yellow arrowheads). Importantly, P-bodies containing PCBP1
were almost always positive for PCBP2 (Fig. 6B, arrows), and P-bodies
lacking PCBP2 appeared invariably negative for PCBP1. Therefore,
PCBP1 seemed present only in PCBP2-positive P-bodies, suggesting a
correlation between the P-body-localization of the two proteins. Since
PCBP1 has been known to associate with PCBP2 [29,30], PCBP1may be
recruited to speciﬁc P-bodies in complex with PCBP2, and possibly
other mRNP factors.
4. Discussion
Our results indicate that PCBP2, possibly in associationwith PCBP1
and other mRNP complexes, dynamically recognizes and accumulates
in speciﬁc P-bodies, likely regardless of its nuclear history. Given that
PCBP2 localizes only to larger P-bodies and neither its overexpression
nor depletion affects the size and number of P-bodies [13], PCBP2 is
likely recruited to P-bodies only at later stages of P-body formation. It
has become increasingly clear that amassment of mRNPs committed
to silencing or degradation forms the ﬁrst step of P-body assembly,
which progresses into microscopically visible P-bodies utilizing
several scaffolding proteins like GW182 and Ge-1 and by further
accumulating non-translating mRNPs [22]. Since such “building
blocks” are ubiquitously present in P-bodies, it does not seem
probable that interaction with these proteins alone will result in the
recruitment of PCBP2. Furthermore, puromycin-induced loading of
repressed mRNPs could not bring about ubiquitous P-body-localiza-
tion of PCBP2 (Fig. 4), suggesting that the presence of PCBP2 likely
reﬂects intrinsic difference among P-bodies rather than stochastic
accumulation, probably originating from the initial step of their
Fig. 6. PCBP1 localizes to a subset of PCBP2-positive P-bodies. (A) HeLa cells transfected with a plasmid encoding YFP-tagged PCBP1 were immunostained for Dcp1a. Arrows indicate
the presence of PCBP1 in P-bodies, whereas arrowheads indicate the absence of PCBP1 in P-bodies. (B) HeLa cells doubly expressing HA-tagged PCBP2 and YFP-tagged PCBP1 were
immunostained using anti-Dcp1a (light blue) and anti-HA antibodies. PCBP1 and PCBP2 were occasionally found to localize concurrently to speciﬁc P-bodies (indicated by arrows).
White arrowheads indicate P-bodies lacking both proteins, whereas yellow arrowheads indicate P-bodies containing PCBP2 but not PCBP1. Nuclei were counterstained with Hoechst
33342. Bars=10 μm.
886 K. Fujimura et al. / Biochimica et Biophysica Acta 1793 (2009) 878–887assembly, i.e. the accumulation of mRNPs in a speciﬁc repressed state.
Since PCBP2 (and PCBP1) is well known to enhance translation of
certain mRNAs and to associate with polysomes, their presence to
particular P-bodies may confer specialized functions, such as the
ability to reverse repression of speciﬁc transcripts in response to
changes in the surrounding environment [3]. Further, recent reports
have shown that miRNAs are required for P-body formation [23,31].
There is a possibility that PCBP2might be recruited to P-bodies largelybecause of its association with mRNAs or proteins involved in miRNA
functions. Indeed, some mRNAs that are reported to associate with
PCBP2, such as transcripts for c-myc [15] and A-Raf-1 kinase [32], are
demonstrated to be targets of speciﬁc miRNAs [33,34]. Moreover,
PCBP2 was identiﬁed to associate with Ago1 (and possibly Dicer) in a
large ribonucleoprotein complex in a recent proteomic study [35],
further lending support to the above hypothesis. It may be that the
observed heterogeneity among P-bodies reﬂects localization of
887K. Fujimura et al. / Biochimica et Biophysica Acta 1793 (2009) 878–887miRNAs and their intended targets bound to PCBP2 to speciﬁc P-
bodies. While the involvement of PCBP2 in miRNA function has not
been established, it will be of great interest to investigate whether its
unique distribution to P-bodies is related to miRNA-mediated
regulation. Together with our observations that PCBP2 localizes to
various types of RNA granules, including stress granules (SGs),
neuronal RNA trafﬁcking granules and perinucleolar compartment
(PNC) (Supplementary Fig. S3), our data further argue for the
possibility that PCBP2, in association with a deﬁned set of mRNP
complexes, modulates post-transcriptional regulation of gene expres-
sion in a distinct manner.
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